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Purpose: To determine whether synthesis of  endogenous basic fibroblast growth factor 
(bFGF) after arterial injury is critical to the intimal thickening response, intraluminal 
adenoviral gene transfer of  an antisense bFGF (Ad.ASbFGF) transgene was used to 
inhibit the subsequent synthesis of  bFGF protein after injury. 
Methods: Sprague-Dawley rats underwent balloon catheter carotid artery injury and in 
vivo gene transfer. Isolated segments of  rat common carotid artery were infected with an 
adenoviral vector encoding an antisense bFGF transcript at concentrations of 2 x 109, 
1 x 101°, or I x 1011 pfu /ml .  Control rats were treated with either a control adenovirus 
encoding the 13-galactosidase g ne, (Ad.lacZ), at 1 x 10 l°, or 1 x 1011 pfu /ml ,  or 
phosphate-buffered saline solution (vehicle). Two weeks after injury the rats were kil led 
and perfusion-fixed. Cross-sectional reas of  the carotid arterial intima and media were 
measured by planimetry, and the in t ima/media  ratio ( I /M)  was calculated for each 
vessel. 
Results: The mean I /M  for each Ad.ASbFGF group and controls were compared and the 
significance assessed by analysis of  variance. At two weeks after injury, the highest dose of  
Ad.ASbFGF,  1 x 1011 pfu /ml ,  resulted in a near total inhibit ion of  thickening ( I /M  = 
0.14 - 0.04, mean + SEM) when compared with phosphate-buffered saline solution 
alone ( I /M  = 0.99 + 0.07), or Ad.lacZ 1 x 10 l° p fu /ml  ( I /M  = 1.01 --_ 0.10) control 
treatments (p < 0.01). A tenfold lower dose of  Ad.ASbFGF,  1 × 101° pfu /ml ,  also 
caused significant reduction in intimal thickening ( I /M  = 0.39 + 0.07, p < 0.01). 
Treatment with 2 x 109 p fu /ml  Ad.ASbFGF did not significantly l imit intimal thicken- 
ing ( I /M  = 0.72 4- 0.12). 
Conclusions: Inhibit ion of  bFGF synthesis in vivo using an antisense RNA strategy 
significantly inhibits intimal thickening after arterial balloon injury. This study suggests 
that continued bFGF synthesis contributes to intimal thickening after arterial injury, and 
that antisense bFGF may represent an effective strategy in l imiting restenosis after 
angioplasty. (J Vase Surg 1997;25:320-5.) 
Neoint imal  hyperplasia is the most common form 
of  vascular remodel ing that occurs in response to 
various forms o f  vascular injury such as angioplasty o f  
normal  and atherosclerotic arteries. 1,2 The arterial 
wall responds to injury with smooth muscle cell 
(SMC) prol i feration and migrat ion of  the vascular 
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SMCs from the media to the intima, narrowing the 
diameter o f  the arterial lumen, s-s Restenosis after 
angioplasty is a frequent clinical problem that causes 
recurrent ischemia in both the peripheral and coro- 
nary circulations, and despite research in this area an 
effective therapy is lacldng. 6,7 
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Both quiescent and proliferating arterial SMCs in 
vivo express basic fibroblast growth factor (bFGF). 
Olsen et al. 8 determined that immunohistochemical 
staining for bFGF is strongly positive in the uninjured 
artery, but falls significantly immediately after arterial 
injury. Western blot analysis of SMC extracts from 
injured and uninjured arteries detect a decrease in the 
total amount of bFGF in the injured arteries, thereby 
confirming the immunostaining results. During the 
2 weeks after injury, the bFGF content gradually 
increases as predominately the i 8kD isoform, rather 
than the 23kD isoform seen in uninjured SMCs. 8,9 
Lindner and Reidy 1° demonstrated that after ar- 
terial injury, addition of exogenous bFGF augments 
the reparative process of intimal hyperplasia. In con- 
trast, they also determined that systemic injection of 
a single dose of neutralizing antibody against bFGF, 
administered atthe time of arterial injury, decreases 
SMC proliferation by 80% at the time of death, 41 
hours after injury (SH thymidine uptake criteria). 
Unfortunately, the single close of neutralizing anti- 
body fails to reduce the intimal esion that develops 
by 8 days. When neutralizing antibody is first given 
on the fourth and fifth clays after arterial injury, it has 
no effect in reducing SMC 3H thymidine uptake at 
41 hours, nor intimal hyperplasia t 8 days. l°,ll 
These studies uggest that preformed bFGF released 
from fragmented SMCs at the time of injury may 
initiate SMC proliferation, but the role of endog- 
enously synthesized bFGF at later times i  unclear. 
Fox and Shanley 12 found that when they infect 
cultured rat aortic SMCs with the adenovirally medi- 
ated antisense bFGF transgene (Ad.ASbFGF), the 
bFGF cellular content is significantly reduced on 
Western analysis. Control SMC cultures treated with 
adenovirally mediated [3-galactosidase g ne transfer 
(Ad.lacZ), or culture medium alone, maintain or- 
mal levels of bFGF. In addition, the SMC cultures 
infected with Ad.ASbFGF exhibit a dose-dependent 
reduction i  survival compared with control cultures.12 
It is not known whether after arterial injury, 
newly synthesized bFGF contributes to cellular 
events, leading to intimal hyperplasia in vivo. To 
study the role of bFGF synthesized in vivo after 
arterial injury, we exposed the carotid artery to a 
recombinant adenovirus encoding ASbFGF RNA, 
delivered locally as a single dose at the time of injury. 
METHODS 
Rat carotid artery model of intimal thickening 
and in vivo gene transfer 
A total of 42 male Sprague-Dawley (SD) rats (300 to 
350 gm; Harlan Sprague-Dawley Inc., Indianapolis, 
Ind.) were anesthetized with intramuscular injection 
of ketamine (50 mg/kg; Aveco Co., Fort Dodge, 
Iowa), xylazine (5 mg/kg; Mobay Corp., Shawnee, 
Kan.), and acepromazine (1 mg/kg; Aveco Co.). 
Routine common carotid balloon catheter arterial 
injury was performed as described by Clowes et al.3 
using a 2F Fogarty balloon catheter (Baxter Health- 
care Corp., Santa Ana, Calif.). is 
After arterial injury and phosphate-buffered saline 
solution (PBS) irrigation of the isolated arterial seg- 
ment, a 50 txl volume ofadenoviral vector in PBS, or 
PBS only, was injected into the lumen of the isolated 
artery and permitted to dwell for 20 minutes at 120 
to 140 mm Hg pressure as described by Schulick et 
al. 13 Each treatment group consisted of eight rats 
receiving one of five treatments as follows: 
Ad.ASbFGF at 2 × ]09 pfu/ml, Ad.ASbFGF at 1 × 
101° pfu/ml, Ad.ASbFGF at 1 X 1011 pfu/ml, PBS 
(vehicle alone) Ad.lacZ at 1 × 101° pfu/ml, or 
Ad.lacZ at 1 X 1011 pfu/ml. 
After treatment, the v ctor solution was with- 
drawn and the artery gently rinsed again with PBS, 
then blood flow was restored to the common and 
internal carotid arteries. The site of injury and treat- 
ment was marked proximally by a 7-0 nylon suture 
placed in adjacent muscle and delimited istally by 
the bifurcation of the common carotid artery. The 
neck incision was closed, and the animal was placed 
on a warming blanket until fully recovered from 
anesthesia. After recovery, the rats were fed normal 
chow and water ad libitum until they were killed. 
Animal care complied with the "Principles of Labo- 
ratory Animal Care" formulated by the National So- 
ciety for Medical Research and the Guide for the Care 
and Use of Laboratory Animals (NIH publication o. 
86-23, revised 1985). 
Monitoring of instillation pressure 
A pressure transducer coupled to a Sirecust 404-1 
monitor (Siemens, Erlangen, Germany) was used to 
measure the delivery pressure of Ad.ASbFGF and 
control treatments. The treatment solution was in- 
jected at a pressure of 120 to 140 mm Hg as recom- 
mended by Schulick et al.13 
Construct ion o f  antisense basic FGF adenoviral 
vector 
The Ad.ASbFGF recombinant adenovirus was con- 
structed by replacement of the [3-galactosidase 
eDNA with a 1.1 kb rat bFGF eDNA (gift of Dr. 
Andrew Baird, Whittier Institute) 14 in the pAd.CMV 
lacZ shuttle vector (gift of Dr. James Wilson, Univer- 
sity of Pennsylvania), followed by homologous recom- 
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bination :5 with the El, E3 deleted, human adenovirus 
serotype 5 mutant dl7001:6 in human embryonal 
kidney 293 cells (American Type Culture Collection, 
Bethesda Md.). Recombinant virus was identified by 
polymerase chain reaction (PCR) amplification of 
recombinant plaques using one vector-specific and 
one insert-specific primer. The vector-specific primer 
(5'-AGA CAT GAT AAG ATA CAT-3') corre- 
sponds to a region of the shuttle vector upstream of 
the insert cloning site but contains no adenoviral 
genomic sequence. The insert-specific primer (5'- 
GCT TCT TCC TGC GCA TCC-3') corresponds to
codons 37-42 of the rat bFGF coding sequence. The 
recombinant virus was twice plaque-purified and ex- 
pression of the antiscnsc transcript confirmed by re- 
verse transcriptase polymerase chain reaction. Total 
cellular RNA (1 ~g), isolated from SMCs infected 
with Ad.ASbFGF, was heat denatured and reverse 
transcribed using random hexamer primers (1 pmol) 
and 200 U reverse transcriptase (Boehringer Mann- 
heim, Indianapolis, Ind.), according to the supplier's 
recommendations. Ten percent of the eDNA prod- 
uct was then amplified using 1 pmol each of a pair of 
bFGF-specific primers (5' primer: 5'-GCA CAC 
ACT CCC TTG ATG GAC AC-3'; 3' primer: 5'- 
GCT TCT TCC TGC GCA TCC-3') that amplify a 
125-base pair product. The PCR was performed 
using 1 U per reaction of Taq polymerase (Boehr- 
inger Mannheim) in a thermal cycler (Ericomp Inc., 
San Diego, Calif.) for 25 cycles using 1 minute steps. 
Denaturation was done at 94 ° C, annealing at 60 ° C, 
and extension at 72 ° C. 
The recombinant adenoviral vector, Ad.CMV 
lacZ, encoding bacterial [3-galactosidase (gift of Dr. 
James Wilson, University of Pennsylvania), 16 was 
used as a viral vector control in these experiments. 
The suspension vehicle, PBS (Bio-Whittaker, Walk- 
ersville, Md.), served as the second control. 
Tissue preparation 
Frozen tissue. All rats were killed with lethal 
doses of anesthesia. Two of eight rats from each 
treatment group were killed 4 days after injury and 
treatment. Tissue samples from those rats were 
quickly harvested, rinsed of blood, and frozen in 
OCT Compound (Miles Inc., Elkhart, Ind.) for test- 
ing the content of [3 galactosidase. The uninjured 
right carotid arteries erved as baseline controls for 
gene transfer testing. 
Formalin fixation. The remaining six of the 
cight rats in each treatment group were killed 2 
weeks after injury, after which the vessels were perfu- 
sion fixed in situ at a perfusion pressure of 120 mm 
Hg. Normal saline solution was instilled first, fol- 
lowed by 10% formalin solution via a large-bore 
cannula placed retrograde in the abdominal aorta. 
The carotid vessels and aortic arch were harvested en 
bloc for further immersion fixation, paraffin embed- 
ding, hematoxylin-eosin staining, and subsequent 
morphometric analysis. All chemicals were of analyt- 
ical grade quality. Cross-section samples of the in- 
jured carotid arteries were taken from the center of 
the injured and treated area. 
Documentation of Ad.lacZ gene transfer to 
carotid tissue 
Animals ldlled on day 4 after injury were evaluated 
for the presence of [3-galactosidase activity, to indi- 
cate successful Ad.lacZ infection a d [3-galactosidase 
expression. Carotid artery specimens (including con- 
trol and Ad.ASbFGF treated injured arteries) were 
processed with X-gal chromagen to detect he pres- 
ence of [3-galactosidase activity. Carotid artery tissue 
samples were thawed and rinsed with PBS to remove 
OCT. The tissues were immersed in PBS for 20 
minutes, then fixed in 2.5% glutaraldehyde (Fisher 
Scientific, Fair Lawn, N.J.) for 15 minutes. Samples 
were rinsed twice in 1 mmol/L MgCI-PBS before 
incubation with the X-gal chromagen mixture (5- 
Bromo-4-chloro- 3 Indolyl-[3-D-galactopyranoside, 
Fisher Scientific, Malvern, Pa.) for 1 hour at 37 ° C. 
Tissues that stained positive for [3-galactosidase ap- 
peared dark blue and contained blue cytoplasmic 
inclusions when magnified. Cross-section and enface 
preparations were examined at 10X and 15X with a 
Leitz dissecting photomicroscope (L ica Inc., Malvern, 
Pa.). Results were recorded as photomicrographs. 
Morphometric analysis of  arterial walt 
Morphometric analysis was performed on cross-sec- 
tioned segments of carotid arteries. A light micro- 
scope (Leitz Laborlux-s, Leica Inc.), fitted with a 
computer interfaced image analyzer (Bioquant Sys- 
tem IV, R&M Biometrics Inc., Nashville, Tenn., and 
Summa Sketch II Plus, Summagraphics Corp., Sey- 
mour, Conn.), was used to calculate the surface area 
of the arterial wall intima and media at a magnifica- 
tion of 125X. The intima to media ratio (I/M) was 
calculated on all perfusion-fixed carotid arteries har- 
vested 2 weeks after injury and treatment. An I /M  of 
1.0 or greater implies that the intimal area is equal to 
or greater than the area of the media. An I /M  of 
0.15 indicates the intimal area is very small. The 
intimal cross sectional area of an uninjured rat artery 
approaches 0, as it is only one endothelial cell layer 
thick. 
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Table I. Comparison of mean intima to media ratios 
Treatment (pfu/ml) n mean I /M  ratio + SEM p (vs lacZ 1 × 101° pfu/ml) p (vs PBS) 
PBS (control vehicle) 6 0.99 -+ 0.07 NS 
Ad.lacZ (control 1 × 101°) 6 1.01 + 0.10 NS 
Ad.lacZ (control 1 × 10 H) 6 1.08 + 0.07 NS NS 
Ad.ASbFGF 2 × 109 6 0.72 + 0.12 NS NS 
Ad.ASbFGF 1 × 10 l° 6 0.39 -+ 0.07 <0.01 <0.01 
Ad.ASbFGF 1 × 10 l~ 6 0.14 + 0.04 <0.01 <0.01 
Comparison of  mean I /M  ratios by analysis of  variance, p values calculated by the Tukey method of post hoc pairwise testing. 
Statistical analysis 
Two weeks after injury, the I /M  was measured onall 
carotid arteries harvested from the formalin perfu- 
sion-fixed animals. The mean I /M  was calculated for 
each group ( + standard error of the mean) and were 
compared to one another by analysis of variance, 
followed by the Tukey method of post hoc pairwise 
testing. A p value of 0.05 or less was considered 
significant (Systat 5.01 for Windows, Systat Incorpo- 
rated). 
Toxicity analysis 
Samples of liver, spleen, skeletal muscle, and aorta 
were harvested from the animals ldlled at 4 days after 
injury and treatment. Each treatment group, 
Ad.ASbFGF, Ad.lacZ, or PBS, contained two ani- 
mals. The organs of animals treated with Ad.lacZ and 
PBS were processed with X-gal chromagen to iden- 
tify uptake of the Ad.lacZ transgene by hematoge- 
nous dispersion. Tissues from all treatment groups 
were fixed in 10% formalin and embedded inparaffin. 
Routine histologic hematocylin and eosin sections of 
the organs were examined for microscopic patho- 
logic changes. 
RESULTS 
Ad.lacZ transgene expression 
Animals killed 4 days after injury and treatment were 
evaluated for the presence ofl3-galactosidasc activity. 
Carotid arteries infected with Ad.lacZ at a concentra- 
tion of 1 × 101° pfu/ml, when processed with X-gal 
chromagen, demonstrated on cross-sectional view 
the depth of arterial wall penetration achieved by 
adenovirally mediated gene transfer. Expression of 
13-galactosidase was noted transmurally, with blue 
staining cytosolic inclusions i  the SMCs of the me- 
dia and adventitia. This finding demonstrates that 
the adcnoviral vector, used to deliver the Ad.lacZ 
transgene, infects the SMCs of the arterial media 
when delivered with a pressure of 120 mm Hg 
after injury. No dctectablc endogenous [3-galacto- 
sidase activity was noted in PBS or Ad.ASbFGF 
treated injured arteries after processing in X-gal 
chromagen. 
Effects of Ad.ASbFGF in the rat carotid artery 
model 
To investigate the effect of adenovirally mediated 
Ad.ASbFGF gene transfer on limiting the intimal 
thickening response to balloon injury, we instilled 
the recombinant vector into the lumen of the left 
carotid artery at the time of injury. At 2 weeks after 
injury and treatment, he I /M  was measured after 
perfusion fixation. Significant inhibition of intimal 
thickening was observed in the groups treated with 
Ad.ASbFGF 1 × 101° and 1 × 1011 pfu/ml when 
compared to PBS and Ad.lacZ controls (Table I). A 
dose-response effect was noted in the Ad.ASbFGF 
treated injured arteries. The lowest dose of 
AdASbFGF, 2 × 109 pfu/ml, resulted in a mean 
I /M  of 0.72. The difference was not  statistically 
significant from the PBS-treated arteries ( I /M  
= 0.99), nor the Ad.lacZ treated arteries ( I /M = 
1.01). A moderate dose ofAd. ASbFGF, 1 × 101° 
pfu/ml, resulted in a mean I /M  of 0.39, and the 
highest dose ofAd. ASbFGF,1 × 1011 pfu/ml, had 
the greatest effect, with a mean I /M  of 0.14. The 
degree of inhibition of intimal thickening with both 
of the higher doses of Ad.ASbFGF was :statistically 
significant (p < 0.01). There was a trend toward a 
lower I /M  in the group treated with the :lowest dose 
of Ad.ASbFGF, though not statistically significant in 
this small sample size (n = 6). The six rats receiving 
treatment with Ad. lacZ virus at a concentration f
I X 1011 pfu/ml showed no difference in the intimal 
thickening response ( I /M = 1.00) when compared 
with rats treated with a lower dose of the same 
vector, Ad.tacZ 1 × 101° pfu/ml ( I /M = 1.01). 
The photomicrographs in Fig. 1 demonstrate the 
inhibition of neointimal thickening in the injured 
artery by Ad.ASbFGF gene transfer compared with 
controls. 
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Fig. 1. Composite of photomicrographs of representative cross-sections from arteries treated 
with either control adenovims transporting Ad.lacZ, the same adenovims transporting 
Ad.ASbFGF, or vehicle alone (PBS). Control arteries are in top row (A-C); bottom row 
contains images of arteries treated with increasing doses of Ad.ASbFGF (left to right). In each 
micrograph, the neointima isdemarcated between two black arrows. Treatment with the lowest 
dose ofAd.ASbFGF, 2 × 10 9 pfu/ml (D), does not significantly decrease neointimal thicken- 
ing compared with control arteries (top row). Ad.ASbFGF at a slightly higher dose, 1 × 101° 
pfu/ml (E), results in a reduction of the intimal thickening response by 66%. Highest dose of 
Ad.ASbFGF, 1 X 1011 pfu/ml (F), shows nearly negligible intimal thickening. The arteries 
depicted in images C and G were treated with the same concentration fadenovirus, 1 x 101° 
pfu/ml, but C was treated with the Ad.lacZ gene, and G was treated with the Ad.ASbFGF 
gene. These images, taken at lower magnification, demonstrate that response to Ad.ASbFGF (a 
66% reduction in neointimal hyperplasia) is uniform along lumen circumference (G). All tissues 
are stained with hematoxylin-eosin except for images A and F, which are prepared with 
elastin-collagen stain to demonstrate he elastin layers ofthe media. Images A, B, D, E, and F 
are magnified by 125X. Images C and G are magnified by 50X. 
Toxicity of Ad.ASbFGF 
Of  the 42 rats included in this study, there were no 
postoperative deaths or complications. There was no 
clinical evidence of overt toxicity related to the ade- 
novirus or to transgene xpression. Light microscopy 
revealed no evidence of  pathologic changes in the 
organs of the animals treated with the adenoviral 
vectors compared with PBS treatment. 
The organs from the rats treated with Ad.lacZ 
and PBS were processed with X-gal chromagen to 
identify uptake of the adenoviral transgene by hema- 
togenous dispersion. Skeletal muscle and thoracic 
aorta were negative for [3-galactosidase. Rarely did a 
cell or cluster of cells (one or two cells per sagittal 
section of liver lobe) show evidence of blue staining 
in the liver. 
DISCUSSION 
bFGF has been shown to be synthesized in the neo- 
intima, but it has not been established that ongoing 
synthesis is required for the response to arterial in- 
jury. We hypothesized that expression of an ASbFGF 
RNA, initiated through adenoviral gene transfer at 
the time of injury, would block new synthesis of 
bFGF during the critical time when SMCs undergo 
proliferation and migration. Antisense inhibition of 
bFGF gene expression should have no effect on pre- 
formed bFGF stores synthesized before arterial in- 
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jury, thus providing a means of distinguishing be- 
tween the roles of these two sources of bFGF. By 
measuring the I /M  ratio 2 weeks after injury, the 
influence of blocldng bFGF synthesis after gene 
transfer was assessed. 
A statistically significant decrease in intimal thick- 
ening resulted from the moderate and high doses of 
Ad.ASbFGF, and the high dose of Ad.ASbFGF al- 
most completely inhibited intimal thickening. To 
attribute specificity of the results to the Ad.ASbFGF 
transgene rather than to toxicity from the vector, we 
used the same adenoviral vector system to deliver the 
Ad.lacZ reporter gene. All such adenovirally treated 
controls demonstrated neointimal thickening, as did 
the PBS treated controls, without significant differ- 
ence noted between the mean I /M  ratios of these 
control groups. 
These results demonstrate that Ad.ASbFGF in- 
hibits intimal thickening at 2 weeks in a dose-depen- 
dent fashion. These results differ from the results of 
Olsen et al. 8 results using neutralizing antibody to 
bFGF. In their study, neutralizing antibody given 
once at the time of injury had no effect on intimal 
thickening at 8 days but did reduce the SMC prolif- 
erative index at 41 hours. These results may be a 
result of rapid clearance of the neutralizing antibody 
soon after systemic delivery so that it was not present 
during the critical time of SMC migration and prolif- 
eration. Alternatively, because the neutralizing anti- 
body was delivered systemically, it may not have had 
access to biologically important cytosolic or nuclear 
sites of  bFGF activity. 
This study demonstrates that an adenovirally ex- 
pressed antisense bFGF RNA, delivered to the arte- 
rial wall at the time of arterial balloon injury, is a 
potent inhibitor of subsequent intimal thickening. 
These in vivo results imply that the arterial reparative 
response relies directly or indirectly on the de novo 
synthesis of bFGF after arterial injury, although the 
mechanism remains to be proven. Adenovirally me- 
diated gene transfer ofASbFGF RNA may represent 
a novel local therapy to enhance the efficacy of pe- 
ripheral and coronary interventions. 
We acknowledge the technical assistance of Jason 
Shanley and Marge Thorell. 
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